4.6 Article

Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study

期刊

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
卷 44, 期 10, 页码 933-939

出版社

WILEY
DOI: 10.1111/eci.12326

关键词

Antihypertensive treatment; brand-name; cardiovascular outcomes; databases; generic; primary prevention

资金

  1. Novartis
  2. Glaxo
  3. Baringer Ingelheim
  4. CVRx
  5. Daiichi Sankyo
  6. Medtronic Vascular Inc
  7. Menarini Int
  8. Merck Serono
  9. Pfizer Inc
  10. Recordati
  11. Servier
  12. Siron
  13. Takeda

向作者/读者索取更多资源

Background Although generic and earlier brand-name counterparts are bioequivalent, their equivalence in preventing relevant clinical outcomes is of concern. Objective To compare effectiveness of generic and brand name antihypertensive drugs for preventing the onset of cardiovascular (CV) outcomes. Design and subjects A population-based, nested case control study was carried out by including the cohort of 78 520 patients from Lombardy (Italy) aged 18 years or older who were newly treated with antihypertensive drugs during 2005. Cases were the 2206 patients who experienced a hospitalization for CV disease from initial prescription until 2011. One control for each case was randomly selected from the same cohort that generated cases. Logistic regression was used to model the CV risk associated with starting on and/or continuing with generic or brand-name agents. Results There was no evidence that patients who started on generics experienced different CV risk than those on brand-name product (OR 0.86; 95% Cl 0.63-1.17). Patients at whom generics were main dispensed had not significantly difference in CV outcomes than those mainly on brand-name agents (OR 1.19; 95% Cl 0.86-1.63). Compared with patients who kept initial brand-name therapy, those who experienced brand-to-generic or generic-to-brand switches, and those always on generics, did not show differential CV risks, being the corresponding ORs (and 95% Cls), 1.18 (0.96-1.47), 0.87 (0.63-1.21) and 1.08 (0.80-1.46). Conclusions Our findings do not support the notion that brand-name antihypertensive agents are superior to generics for preventing CV outcomes in the real-world clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据